175135-32-7

Basic information

• Product Name: 2-AMINO-4-(3,4-DIFLUOROPHENYL)THIAZOLE
• Synonyms: BUTTPARK 41\03-35;AKOS BBS-00006572;4-(3,4-DIFLUOROPHENYL)-1,3-THIAZOL-2-AMINE;4-(3,4-DIFLUORO-PHENYL)-THIAZOL-2-YLAMINE;2-AMINO-4-(3,4-DIFLUOROPHENYL)THIAZOLE;TIMTEC-BB SBB005523;2-Amino-4-(3,4-difluorophenyl)-1,3-thiazole;2-Amino-4-(3,4-difluorophenyl)-1,3-thiazole 97%
• CAS NO: 175135-32-7
• Molecular Formula: C₉H₆F₂N₂S
• Molecular Weight: 212.22
• Product Categories: Thiazoles;Building Blocks;Heterocyclic Building Blocks;Building Blocks;C8 to C9;Chemical Synthesis;Fluorinated Building Blocks;Heterocyclic Building Blocks;Heterocyclic Fluorinated Building Blocks;Other Fluorinated Heterocycles
• Mol File: 175135-32-7.mol
• Article Data: 11

Chemical Properties

• Melting Point: 121-125 °C(lit.)
• Boiling Point: 361.784 °C at 760 mmHg
• Flash Point: 172.601 °C
• Appearance: White to pale brown/Solid
• Density: 1.433 g/cm³
• Vapor Pressure: 6.36E-07mmHg at 25°C
• Refractive Index: 1.577
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-AMINO-4-(3,4-DIFLUOROPHENYL)THIAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-4-(3,4-DIFLUOROPHENYL)THIAZOLE(175135-32-7)
• EPA Substance Registry System: 2-AMINO-4-(3,4-DIFLUOROPHENYL)THIAZOLE(175135-32-7)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 22-36
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 175135-32-7(Hazardous Substances Data)

Usage

General Description

2-Amino-4-(3,4-difluorophenyl)thiazole is a compound categorized under the class of organic compounds known as thiazoles. The thiazoles are heterocyclic compounds containing a five-member aromatic ring made up of one sulfur atom, one nitrogen atom, and three carbon atoms. In the case of 2-Amino-4-(3,4-difluorophenyl)thiazole, the thiazole ring is substituted with an amino group at position 2 and a 3,4-difluorophenyl group at position 4. The presence of the fluorine atoms can impact the compound’s reactivity, making it potentially useful in various pharmaceutical or industrial applications. However, specific properties, toxicity, and application-related information for this precise chemical are not extensively documented and therefore necessitate further study.

InChI:InChI=1/C15H11ClFNO/c16-14-2-1-3-15(17)13(14)10-19-12-6-4-11(5-7-12)8-9-18/h1-7H,8,10H2

Upstream product

• 40706-98-7 3,4-difluorophenacyl bromide 
• 17356-08-0 thiourea 
• 369-33-5 3',4'-difluoroacetophenone 

Downstream Products

• 1376446-83-1 4-((4-(3,4-difluorophenyl)thiazol-2-yl)amino)-4-oxobutanoic acid 
• 1007788-41-1 C₁₄H₁₂F₂N₂O₃S 
• 372094-86-5 N-[4-(3,4-Difluorophenyl)thiazol-2-yl]-(2-chloro-5-nitrophenyl)carboxamide 

Relevant articles and documents

Development of 2-amino-4-phenylthiazole analogues to disrupt myeloid differentiation factor 88 and prevent inflammatory responses in acute lung injury

Myeloid differentiation primary response protein 88 (MyD88), an essential adapter protein used by toll-like receptors (TLR), is a promising target molecule for the treatment of respiratory inflammatory diseases. Previous studies explored the activities of novel 2-amino-4-phenylthiazole analogue (6) in inflammation-induced cancer, and identified the analogue as an inhibitor of MyD88 toll/interleukin-1 receptor (TIR) homology domain dimerization. Here, we describe the synthesis of 47 new analogues by modifying different sites on this lead compound and assessed their anti-inflammatory activities in lipopolysaccharide-induced mouse primary peritoneal macrophages (MPMs). The most promising compound, 15d, was found to effectively interact with MyD88 protein and prevented formation of the MyD88 homodimeric complex. Furthermore, 15d showed in vivo anti-inflammatory activity in LPS-caused model of acute lung injury. This work provides new candidates as MyD88 inhibitors to combat inflammation diseases.

Halides Held by Bifurcated Chalcogen-Hydrogen Bonds. Effect of μ(S,N-H)Cl Contacts on Dimerization of Cl(carbene)PdII Species

The reaction of cis-[PdCl2(CNCy)2] (1) with thiazol-2-amines (2-10) leads to the C,N-chelated diaminocarbene-like complexes [PdCl{C(N(H)4,5-R2-thiazol-2-yl)NHCy}(CNCy)] (11-14; 82-91%) in the case of 4,5-R2-thiazol-2-amines (R, R = H, H (2), Me, Me (3), -(CH2)4- (4)) and benzothiazol-2-amine (5) or gives the diaminocarbene species cis-[PdCl2{C(N(H)Cy)N(H)4-R-thiazol-2-yl}(CNCy)] (15-19; 73-93%) for the reaction with 4-aryl-substituted thiazol-2-amines (R = Ph (6), 4-MeC6H4 (7), 4-FC6H4 (8), 4-ClC6H4 (9), 3,4-F2C6H3 (10)). Inspection of the single-crystal X-ray diffraction data for 15-17 and 19 suggests that the structures of all these species exhibit previously unrecognized bifurcated chalcogen-hydrogen bonding μ(S,N-H)Cl and also PdII···PdII metallophilic interactions. These noncovalent interactions collectively connect two symmetrically located molecules of 15-17 and 19, resulting in their solid-state dimerization. The existence of the μ(S,N-H)Cl system and its strength (6-9 kcal/mol) were additionally verified/estimated by a Hirshfeld surface analysis and DFT calculations combined with a topological analysis of the electron density distribution within the formalism of Bader's theory (AIM method) and NBO analysis. The observed noncovalent interactions are jointly responsible for the dimerization of 15-19 not only in the solid phase but also in CHCl3 solutions, as predicted theoretically by DFT calculations and confirmed experimentally by FTIR, HRESI-MS, 1H NMR, and diffusion coefficient NMR measurements. Available CCDC data were processed under the new moiety angle, and the observed μ(S,E-H)Cl systems were classified accordingly to E (E = N, O, C) type atoms.

Design, synthesis and biological evaluation of thiazole- and indole-based derivatives for the treatment of type II diabetes

Present studies have shown that the lipid carrier has a significant role in several aspects of metabolic syndrome in A-FABP/ap2-deficient mice, including type 2 diabetes and atherosclerosis. 38 Thiazole- and indole-based derivatives were synthesized and investigated for their inhibitory effects on the production of LPS-stimulated TNF-α. Among them, 12b exhibited an excellent inhibitory efficiency compared to BMS309403 (95% vs. 85%) at the concentration of 10 μM and a binding affinity for ap2 with the apparent Ki values 33 nM. Oral administration of 12b at a dosage of 50 mg/kg effectively reduced the levels of plasma blood glucose, triglycerides, insulin, total cholesterol and alanine aminotransferase in high-fat/diet-induced obesity model. The results highlighted that 12b was a potent anti-diabetic agent.